MTF Biologics to Highlight Portfolio of Wound Care Solutions at SAWC Fall

“MTF Biologics Wound Care is different by design,” said Kim Rounds, Vice President of Wound Care at MTF Biologics. “We are committed to providing effective solutions for those with chronic wounds, while honoring the gift of donated tissue. We understand that people with chronic wounds face a myriad of health challenges, and we aim to advance research and development of new solutions that can aid in patient outcomes.”

The nonprofit organization will feature its full line of biologic wound care solutions:

• AmnioBand® Membrane, an aseptically processed human allograft placental matrix comprised of amnion and chorion for use as an acute or chronic wound covering.
• AmnioBand® Particulate, an aseptically processed human allograft that retains the structural properties of the extracellular matrix.
• AlloPatch® Pliable Allograft Dermal Matrix, an aseptically processed human reticular dermal tissue for use as a chronic or acute wound covering.
• AmnioBand® Viable, a cryopreserved human allograft that is aseptically processed to retain its inherent components and a viable population of cells.

“It’s a pleasure to be at this year’s fall symposium and to have the opportunity to feature our wound care innovations,” said Marc Long, PhD, Vice President of Research and Development at MTF Biologics. “We have collaborated with healthcare providers across the nation to develop dermal and placental tissue forms that are minimally processed to be easy for clinicians to apply and promote natural wound closure, by facilitating cell attachment and preserving the body’s natural structure. We look forward to continuing vital conversations about wound care professionals’ challenges and moving forward on additional efforts to advance progress in this essential field.”

MTF Biologics will host an Industry Supported Symposium titled, “Different by Design-- AmnioBand® Allograft Placental Matrix—New Level I Evidence for Wound Closure of DFUs and VLUs,” where three of the leading names in wound care research, Charles Zelen, DPM, FACFAS, Moderator; Lawrence DiDomenico, DPM, FACFAS; and Paul M. Glat, MD, FACS, will present on published research around Level 1 clinical outcomes that used placental allografts. The symposium will be held at Milano VII-VIII on Sunday, October 13, at 7:30 a.m.

A series of clinical and scientific posters from MTF Biologics researchers will round out the Symposium with presentations held at the poster reception 5:15 to 6:15 p.m. on Sunday, October 13. These posters include:

• CS-023 Innovative Combination Therapy with Novel Allograft Tissues in Aiding Natural Wound Closure of Complex Wounds
• CS-024 Addressing Complex Wounds with Aseptically Processed Pre-meshed Human Reticular Dermal Allografts
• LR-020 Aseptically Processed Meshed Human Reticular Dermal Allografts Help to Facilitate Surgical Wound Closure by Providing a Scaffold in Support of Angiogenesis and Granulation Activities
• LR-010 Allograft Adipose Matrix: A Natural Off-the-Shelf Solution that Supports Adipose Tissue Formation and Soft Tissue Augmentation for the Diabetic Foot in Remission
• CR-026 - A Prospective, Randomized, Controlled, Multi-Center Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft Application Versus Standard of Care in the Management of Non Healing Venous Leg Ulcers Abstract
• CR-009 A Prospective Multi-center Study of a Weekly Application Regimen of Viable Human

Industry expert Dr. Michael Desvigne will discuss MTF Biologics’ wound care offerings at the MTF Biologics’ booth #121, while the exhibit hall is open.

For more information on MTF Biologics, please visit www.mtfbiologics.org.

About MTF Biologics

MTF Biologics is a global nonprofit organization on the forefront of saving and healing lives through innovations in tissue and organ donation, transplantation, and research. We collaborate with leading physicians, scientists, and experts in tissue and organ recovery to honor donated gifts, serve patients and advance science. We create the highest quality and safest tissue grafts, and fund clinicians and researchers furthering the science of transplantation. Our subsidiary, International Institute for the Advancement of Medicine (IIAM), provides non-transplantable organs and tissues to the medical research community for purposes of combatting and curing disease. Our subsidiary, Statline, offers specialized communications and technology expertise to organ, tissue and eye procurement organizations, as well as the hospitals and patients they serve. Our sister organization, Deutsches Institute fur Zell-Und Gewebeersatz (DIZG), expands our reach in Europe. For more information, visit www.mtfbiologics.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005044/en/